Skip to main content
Novartis AG logo

Novartis AG — Investor Relations & Filings

Ticker · NOVN ISIN · CH0038459415 LEI · 5493007HIVTX6SY6XD66 SW Manufacturing
Open in API
Filings indexed 1,070 across all filing types
Latest filing 2014-10-06 Regulatory Filings
Country CH Switzerland
Listing SW NOVN

About Novartis AG

https://www.novartis.com/

Novartis AG is a global medicines company focused on the research, development, manufacturing, and marketing of innovative healthcare products. The company's mission is to reimagine medicine to improve and extend people's lives. By leveraging advanced science and technology, Novartis develops a portfolio of treatments across various therapeutic areas to address the evolving needs of patients and societies. The firm is committed to delivering high-value medicines that tackle some of the most challenging healthcare issues worldwide.

Recent filings

Filing Released Lang Actions
6-K
Regulatory Filings Classification · 95% confidence The document is a Form 6-K filed by Novartis International AG, which is a report of a foreign private issuer pursuant to the Securities Exchange Act of 1934. The content is a media release announcing a clinical collaboration with Bristol-Myers Squibb to evaluate immunotherapy combinations for NSCLC. It includes detailed information about the collaboration, investigational drugs, safety information, and forward-looking statements. There are no financial statements or comprehensive financial performance data presented. The document is not an annual or interim report, earnings release, or any other financial report type. It is a regulatory filing providing material information to the SEC and investors about a significant corporate development. Therefore, it fits best under Regulatory Filings (RNS). The document length is substantial (15,000 characters), indicating it is not a brief announcement but a full regulatory filing. Confidence is high due to the clear identification as Form 6-K and the nature of the content.
2014-10-06 English
FORM 4 SUBMISSION
Director's Dealing
2014-09-24 English
FORM 3 SUBMISSION
Director's Dealing
2014-09-17 English
S-8
Capital/Financing Update Classification · 95% confidence The document is a Form S-8 Registration Statement filed with the SEC by Novartis AG. Form S-8 is used for registering securities to be offered under employee benefit plans, such as stock options or incentive plans. The text includes details about the securities to be registered, references to prior filings including annual reports and interim reports, and legal indemnification information. It is not a financial report like an Annual Report (10-K) or Interim Report (IR), nor is it an announcement or proxy material. It is a registration statement related to capital raising through employee plans, which fits the Capital/Financing Update category (CAP). The document length is substantial and contains detailed registration information, not just an announcement or certification. Therefore, the appropriate classification is Capital/Financing Update (CAP).
2014-09-12 English
Regulatory Filings 2014
Regulatory Filings Classification · 100% confidence The document is a Form F-6 Registration Statement filed with the SEC for the registration of American Depositary Shares evidenced by American Depositary Receipts (ADRs) for Novartis AG. It includes details about the securities to be registered, the deposit agreement, legal opinions, certifications, and signatures of company officers and directors. The document is a regulatory filing related to securities registration under the Securities Act of 1933, specifically for ADRs. It is not a financial report, earnings release, or management discussion, nor is it an announcement of voting results or a proxy statement. It is a formal registration statement filing with the SEC, which fits best under the category of Regulatory Filings (RNS). The document length is over 12,000 characters and contains substantive legal and registration information, not just an announcement or certification alone.
2014-09-08 English
6-K
Regulatory Filings Classification · 95% confidence The document is a Form 6-K filing by Novartis AG, which is a report of a foreign private issuer pursuant to the Securities Exchange Act of 1934. The content is a media release announcing clinical trial results for a new heart failure medicine, LCZ696, including study outcomes, safety data, and future regulatory plans. It is not a full financial report, audit report, or earnings release. It is a regulatory announcement providing material information to investors and the public about clinical trial results and product development progress. The document is lengthy (15,000 characters) and contains detailed information but is primarily a press release-type regulatory filing rather than a financial or management report. Therefore, the best classification is Regulatory Filings (RNS), which is the fallback category for miscellaneous regulatory announcements that do not fit other specific categories.
2014-09-02 English

Browse filings by year

18 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.